News - Ipsen, Oncology

Filter

Current filters:

IpsenOncology

Popular Filters

Ipsen posts top results for Phase III study of Decapeptyl in prostate cancer

Ipsen posts top results for Phase III study of Decapeptyl in prostate cancer

07-02-2014

French drugmaker Ipsen has announced that the Phase III clinical trial evaluating Decapeptyl (triptorelin…

DecapeptylFranceIpsenOncologyPharmaceuticalResearch

Ipsen, a good European mid-cap to watch, says US analyst

Ipsen, a good European mid-cap to watch, says US analyst

27-01-2014

Most American investors are familiar with large European drugmakers like Sanofi and Novartis but the…

FinancialIpsenOncologyPharmaceuticalResearchSomatulinetasquinimod

Ipsen implements new US governance to prepare for Somatuline launch in oncology

Ipsen implements new US governance to prepare for Somatuline launch in oncology

22-01-2014

French drugmaker Ipsen (Euronext: IPN) has announced new governance in the USA following its decision…

BoardroomIpsenOncologyPharmaceuticalSomatulineUSA

Ipsen reveals positive results for Somatuline

Ipsen reveals positive results for Somatuline

17-01-2014

French drugmaker Ipsen (Euronext: IPN) has announced that Somatuline Autogel/Somatuline Depot (lanreotide)…

FranceIpsenOncologyPharmaceuticalResearchSomatuline

Dominique Brard joins Ipsen as Executive Vice President of Human Resources

Dominique Brard joins Ipsen as Executive Vice President of Human Resources

19-12-2013

French pharmaceutical company Ipsen has announced the appointment of Dominique Brard as Executive Vice…

BoardroomEuropeIpsenNeurologicalOncologyPharmaceutical

Highlights from European Cancer Congress on Kadcyla, Yervoy, Erbitux and Somatuline

30-09-2013

A host of new oncology data was presented at the European Cancer Congress in Amsterdam, the Netherlands,…

Bristol-Myers SquibbErbituxEuropeIpsenKadcylaMerck KGaAOncologyPharmaceuticalResearchRocheSomatulineYervoy

Trial finds Ipsen's tumor drug Somatuline superior to placebo in delaying disease progression

11-07-2013

French drugmaker Ipsen (Euronext: IPN) has announced positive results from its Phase III study of Somatuline…

EuropeIpsenOncologyPharmaceuticalResearchSomatuline

News briefs on Ipsen/Galderma and YM BioSciences nimotuzumab assets

04-12-2012

French drugmaker Ipsen (Euronext: IPN) and Switzerland-headquartered Galderma have expanded their collaboration…

Asia-PacificBiotechnologyCIMABDysportGaldermaInnoKeys PTEIpsenLicensingnimotuzumabOncologyPharmaceuticalSouth AmericaYM Biosciences

Global neuroendocrine carcinoma market to reach $475 million by 2019; report

04-07-2012

The global Neuroendocrine carcinoma therapeutics market was worth $127 million in 2011 and now the market…

AvastinBioSynthemaIpsenLutatheraMarkets & MarketingOncologyPharmaceuticalRocheSomatuline

Milestone for Active Biotech in tasquinimod collaboration with Ipsen

22-05-2012

Sweden's Active Biotech (Nasdaq OMX Nordic: ACTI) has received a 10 million-euro ($127 million) milestone…

Active BiotechBiotechnologyFinancialIpsenOncologyPharmaceuticalResearchtasquinimod

Ipsen enters deal with Photocure to commercialize Hexvix

28-09-2011

French drugmaker Ipsen (Euronext: IPN) has entered into a partnership with Norway-based Photocure (OSE:…

HexvixIpsenLicensingOncologyPharmaceuticalPhotocure

Back to top